Furthermore, Valeant is confident it can succeed in its $50 billion takeover attempt of Allergan (NYSE: AGN), best known for anti-wrinkle treatment Botox. Given Valeant CEO Michael Pearson's track record of great acquisitions, this would also likely be great news for shareholders. And in this case Mr. Pearson even has the endorsement of activist investor Bill Ackman.